Search for a trial | Research with human participants

1 results

AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSE-ESCALATION AND EXTENSION, PHASE IA/IB STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-503749-76-00 check the CTIS register for the current data. This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of…